Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Files An 8-K Regulation FD DisclosureItem 7.01
On November 14, 2017, the Company issued the press release attached hereto as Exhibit 99.1. Spokespersons of the Company plan to present the information in the presentation slides attached hereto as Exhibit 99.2.
The furnishing of the attached press release and presentation is not an admission as to the materiality of any information therein. The information contained in the press release and presentation is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the U.S. Securities and Exchange Commission, or the SEC, and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the “Safe Harbor” section of the press release in Exhibit 99.1 attached hereto and the slide titled “Safe Harbor and Disclaimer” in Exhibit 99.2 attached hereto.
The information in this Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1 and 99.2 attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, in the press release attached as Exhibit 99.1 to this Current Report and in the presentation attached as Exhibit 99.2 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
| Item 7.01 | Financial Statements and Exhibits. |
(d) Exhibits.
PROTEOSTASIS THERAPEUTICS, INC. ExhibitEX-99.1 2 d475090dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update Preliminary Data from PTI-428 + Orkambi 28 Day Clinical Study on Track for Q4 2017 Initial Data from PTI-801 + Orkambi 14 Day Clinical Trial Anticipated in Q4 2017 Initial Data from PTI-808 SAD and MAD HV 7 day Study Anticipated in Q4 2017 Initial Data from PTI-808 + PTI-801 + PTI-428 coadministration HV 7 day Study Anticipated in Q4 2017 Dual Combination CF Clinical Study of PTI-801 + PTI-808 Expected to Initiate in Q4 2017 Preliminary Data from PTI-428 + Kalydeco 14 Day Clinical Study Anticipated in Q1 2018 Triple Combination CF Study of PTI-428 + PTI-801 + PTI-808 Planned to Initiate in 1H 2018 CAMBRIDGE,…To view the full exhibit click here
About Proteostasis Therapeutics, Inc. (NASDAQ:PTI)
Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.